Sign In
19 May 2022 14:01
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.
19 May 2022
Ideagen PLC
("Ideagen" or the "Company")
Rule 2.9 Announcement
As announced earlier today, the Company allotted a total of 3,955 new ordinary shares of 1 penny each in the capital of the Company ("Ordinary Shares") on 18 May 2022 following purchases made under the Company's Share Incentive Plan ("SIP").
Following issue of the Ordinary Shares, the number of Ordinary Shares in issue and admitted to trading on AIM will be 293,753,784. This figure of 293,753,784 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
The Ordinary Shares are relevant securities of Ideagen plc for the purposes of Rule 8 of The City Code on Takeovers and Mergers (the "Code"). In accordance with Rule 2.9 of the Code, Ideagen confirms that it has in issue 293,753,784 Ordinary Shares and admitted to trading on the AIM Market of the London Stock Exchange. The Company has no Ordinary Shares held in Treasury. The International Securities Identification Number for Ideagen Ordinary Shares is GB00B0CM0C50.
Enquiries:
Ideagen plcBen Dorks, Chief Executive OfficerEmma Hayes, Chief Financial Officer | 01629 699 100 |
|
|
Goldman Sachs International (Financial Adviser to Ideagen) Chris EmmersonKhamran Ali | 020 7774 1000 |
|
|
Canaccord Genuity Limited (Nomad)Simon Bridges Georgina McCooke | 020 7523 8000 |
| |
FTI ConsultingJamie RickettsDwight BurdenValerija Cymbal | 020 3727 1000 ideagen@fticonsulting.com |
About Ideagen plc
Ideagen's software helps companies comply with regulation and manage risk.
Ideagen is a leader in the +$30 billion regulatory and compliance software market, serving highly regulated industries such as life sciences, healthcare, banking and finance and insurance.
More than 8,000 customers use Ideagen's software, including leading accounting and pharmaceutical firms.
Ideagen has a track record of 12 years of profitable growth and strong cash generation with high levels of recurring revenues (representing an expected 86% of total revenues for the year ended 30 April 2022).
Ideagen has a diversified customer base including blue chip, global brands such as Heineken, British Airways, Aggreko, Bank of New York and Johnson Matthey.
Ideagen is headquartered in the UK, listed on the London Stock Exchange AIM market (Ticker: IDEA.L), and has key hubs in the UK, USA, Middle East and South East Asia. For further information please visit www.ideagen.com.
Miscellaneous
Goldman Sachs International, which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom, is acting exclusively for Ideagen and no one else in connection with the matters set out in this announcement and will not be responsible to anyone other than Ideagen for providing the protections afforded to clients of Goldman Sachs International nor for providing advice in connection with the contents of this announcement or any other matter referred to herein.
Canaccord Genuity Limited ("Canaccord Genuity"), which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting exclusively for Ideagen and no one else in connection with the matters set out in this announcement and will not be responsible to anyone other than Ideagen for providing the protections offered to clients of Canaccord Genuity or for providing advice in relation to the contents of this announcement or any matters referred to herein.
Follow the stocks
